These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 18323273)
21. The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion. Li Q; Bavikatty N; Michael CW Semin Diagn Pathol; 2006 Feb; 23(1):15-9. PubMed ID: 17044191 [TBL] [Abstract][Full Text] [Related]
22. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030 [TBL] [Abstract][Full Text] [Related]
23. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1]. Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046 [TBL] [Abstract][Full Text] [Related]
24. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845 [TBL] [Abstract][Full Text] [Related]
25. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis. Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions. Hafez NH; Tahoun NS J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843 [TBL] [Abstract][Full Text] [Related]
27. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268 [TBL] [Abstract][Full Text] [Related]
28. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect]. Marsan C; Gaulier A; Sabatier P; Garcia R Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583 [TBL] [Abstract][Full Text] [Related]
29. Immunocytochemical profile of benign and carcinomatous effusions. A practical approach to difficult diagnosis. Esteban JM; Yokota S; Husain S; Battifora H Am J Clin Pathol; 1990 Dec; 94(6):698-705. PubMed ID: 1700877 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Afify AM; al-Khafaji BM Acta Cytol; 2002; 46(4):675-8. PubMed ID: 12146029 [TBL] [Abstract][Full Text] [Related]
31. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Riera JR; Astengo-Osuna C; Longmate JA; Battifora H Am J Surg Pathol; 1997 Dec; 21(12):1409-19. PubMed ID: 9414184 [TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical panel for distinguishing between carcinoma and reactive mesothelial cells in serious effusions. Lee JS; Nam JH; Lee MC; Park CS; Juhng SW Acta Cytol; 1996; 40(4):631-6. PubMed ID: 8693877 [TBL] [Abstract][Full Text] [Related]
33. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
34. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type]. Klech H; Rona G; Hutter C; Bayer PM; Kummer F Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811 [TBL] [Abstract][Full Text] [Related]
35. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy. Kobzik L; Antman KH; Warhol MJ Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of impact of immunocytochemical techniques in cytological diagnosis of neoplastic effusions. Linari A; Bussolati G J Clin Pathol; 1989 Nov; 42(11):1184-9. PubMed ID: 2685053 [TBL] [Abstract][Full Text] [Related]
37. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191 [TBL] [Abstract][Full Text] [Related]
38. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
39. Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal. Longatto Filho A; Alves VA; Kanamura CT; Nonogaki S; Bortolan J; Lombardo V; Bisi H Acta Cytol; 2002; 46(4):651-8. PubMed ID: 12146025 [TBL] [Abstract][Full Text] [Related]
40. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]